Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
Paradigm BioCapital and affiliated reporting persons disclosed passive beneficial ownership of UroGen Pharma Ltd. ordinary shares. The Adviser, the Adviser GP and Senai Asefaw each report sole beneficial ownership of 2,332,066 shares, equal to 5.0% of the outstanding class, while Paradigm BioCapital International Fund Ltd. reports 2,056,187 shares or 4.4%. These percentages are calculated using 46,264,132 ordinary shares outstanding as reported by the issuer.
The statement is filed on Schedule 13G, which the reporting persons use to indicate passive holdings; the filing includes a certification that the shares were not acquired to change or influence control and disclaims beneficial ownership beyond the shares directly held. Principal business addresses and organizational jurisdictions for each reporting person are provided.
Form 144 filed for UroGen Pharma Ltd. (URGN) reports a planned insider disposition.
- Securities: 5,149 ordinary shares.
- Estimated value: $97,573.55.
- Broker: Oppenheimer & Co., NASDAQ execution targeted for 28 Jul 2025.
- Total shares outstanding: 46,107,451; proposed sale equals ~0.011% of float.
- Share origin: Restricted Stock Units granted 31 Jan 2024 (10,000 units).
- Prior activity: Same seller disposed of 5,162 shares for $38,043.94 on 9 Jun 2025.
The filer certifies no undisclosed adverse information under Rule 144. Given the modest volume relative to outstanding shares, the transaction is unlikely to have a material price impact but continues a pattern of insider selling that investors may monitor.